封面
市場調查報告書
商品編碼
2173048

siRNA治療市場:全球市場預測,2026-2032年

siRNA Therapeutics Market - Global Forecast 2026-2032

出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年,siRNA 療法市場將成長至 66.1 億美元,複合年成長率為 10.68%。

主要市場統計數據
基準年 2025 32.5億美元
預計年份:2026年 35.8億美元
預測年份 2032 66.1億美元
複合年成長率 (%) 10.68%

siRNA治療藥物:概述

小干擾RNA(siRNA)療法是一種旨在透過誘導細胞機制分解互補傳訊RNA來選擇性定序特定基因的藥物。其臨床價值在於其高度靶向特異性、能夠靶向以往難以治療的蛋白質靶點,以及在遞送系統確保持續活性的情況下,降低給藥頻率的潛力。該領域正透過序列設計、化學穩定性、結合以及組織特異性遞送等方面的改進而不斷進步。

遞送、持久性和臨床應用方面的進步正在重塑這一領域。

該領域的研究趨勢正從驗證基因靜默轉向確保藥物可靠地遞送至臨床重要組織。配體偶聯物、脂質體系統和其他遞送方法正在不斷改進,以提高攝取效率、減少脫靶效應並延長藥理活性持續時間。基於生物標記的開發、對劑量反應特徵的更清晰闡明,以及對生產一致性、長期安全性、免疫影響和治療可及性的日益關注,也在推動該領域的發展。

人工智慧正在加速設計、優先排序和開發。

人工智慧 (AI) 透過輔助標靶識別、序列最佳化、脫靶預測、遞送載體選擇以及轉錄組和臨床資料集分析,為 siRNA 的發現做出了貢獻。其累積影響取決於訓練資料的品質和多樣性、實驗檢驗以及透明的模型管治。雖然 AI 可以縮短迭代周期並提高候選化合物的優先排序,但它無法取代實驗室驗證、毒性測試、監管審查或治療後監測。

區域洞察:交付能力和監管合規性是影響採用的關鍵因素。

北美憑藉其成熟的生物技術基礎設施、臨床研究能力以及在先進療法方面的豐富經驗,佔優勢。歐洲則將強大的學術轉化網路與監管和衛生技術評估的協調努力相結合。亞太地區受益於不斷擴展的生物製藥能力和積極的研發活動,但報銷體系和臨床基礎設施的區域差異仍然是重大挑戰。拉丁美洲的專業研究和治療能力正在發展,但可近性和供應鏈可靠性仍然影響著科技的普及應用。中東的精準醫療和創新生態系統正在不斷加強,而非洲則需要對臨床網路、診斷技術、冷鏈物流和公平獲取醫療資源進行持續投資。

群體洞察:協作和政策一致性影響規模化

在東協市場,由於監管體系、醫療結構和醫療服務取得條件的多樣性,區域間合作尤其重要。金磚國家成員國擁有大規模的科學研究人員和病患群體,以及不同的研發和報銷環境。歐盟擁有監管協調機制,但各國在醫療技術評估和採購方面仍有差異。七國集團(G7)國家具備先進的研發、生產及資金籌措能力。海灣合作理事會(GCC)國家正致力於醫療現代化和精準醫療,而北約成員國則擁有廣泛的研究和產業網路。由於這些群體並非同質市場,因此實施策略必須考慮各國政策和基礎設施的差異。

國別概況:每個國家的優勢造就了不同的發展路徑

美國和加拿大擁有強大的科學研究體系和經驗豐富的臨床開發環境。英國、德國、法國、義大利和西班牙已建立起完善的學術和醫療網路,但評估、採購和報銷方面的差異影響了技術的採納。中國、日本、韓國、印度和澳洲正透過其獨特的監管和醫療框架,不斷提升自身的研究、生產和轉化研究能力。巴西和墨西哥是拉丁美洲臨床活動和醫療服務的重要中心,其准入受制於機構能力和供應鏈。俄羅斯擁有科學研究和臨床能力,但其合作、採購和監管環境需要仔細評估。

siRNA治療領域領導者的策略重點

產業領導者應優先考慮根據自身機構的生物學特性量身定做的遞送平台,儘早評估脫靶效應和免疫風險,並利用具有臨床意義的生物標記來證明療效的持續性。研發計畫應整合生產控制、可擴展的分析方法以及清晰的長期追蹤。與醫院、診斷服務提供者、監管機構和患者團體建立合作關係將有助於改善臨床試驗的實施和准入計劃。在部署人工智慧時,檢驗的資料集、人工監督、可重複的工作流程以及偏差、隱私和模型漂移的明確控制措施至關重要。區域上市策略應反映當地的保險報銷機制、基礎設施和治療監測要求,而不是依賴全球統一的路徑。

調查方法:基於證據對siRNA治療藥物的現狀進行評估。

本執行摘要系統地整合並分析了公開的科學文獻、臨床試驗記錄、監管文件、醫療保健系統資訊以及權威的政策和技術資訊來源。證據從相關性、時效性、方法學有效性和地域適用性等方面進行了定性評估。研究結果根據治療機制、給藥技術、研發實踐、人工智慧應用以及區域、群體和國家的具體情況進行分類。本摘要未提供市場估算、預測、市場規模計算、市場佔有率或展望。

結論:精準的實施和嚴謹的、以證據為基礎的方法將決定未來的進展。

siRNA療法正朝著更成熟的模式發展,這需要將選擇性基因靜默與可靠的組織遞送、持續的療效、可控的安全性以及可及的治療方案相結合。儘管科學進步得益於分析技術的改進和人工智慧驅動的優先排序,但成功仍取決於實驗檢驗和可靠的臨床證據。能夠將平台創新與嚴謹的生產製造、監管合作、醫療保健系統的實際情況以及患者需求相協調的機構,將最有能力將基因靜默的科學轉化為永續的臨床價值。

目錄

第1章:序言

第2章:調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章:人工智慧的累積影響,2026年

第7章 siRNA治療市場:依藥物分類

  • 玉簪
  • 因克利斯矽烷
  • 魯馬什蘭
  • 內度四蘭
  • 糕點師
  • 伏特里西蘭

第8章 siRNA治療市場:依遞送系統分類

  • 脂質奈米顆粒
  • 胜肽遞送系統
  • 聚合物共軛物

第9章 siRNA治療市場:依給藥途徑分類

  • 靜脈注射(IV)
  • 皮下

第10章:siRNA治療市場:依治療領域分類

  • 心血管疾病
  • 免疫系統疾病
  • 感染疾病
    • 細菌感染疾病
    • 病毒感染疾病
  • 代謝性疾病
  • 神經病變
    • 阿茲海默症
    • 帕金森氏症
  • 腫瘤學
    • 骨髓惡性腫瘤
      • 白血病
      • 淋巴瘤
    • 固體癌
      • 乳癌
      • 肺癌
      • 攝護腺癌

第11章 siRNA治療市場:依最終用戶分類

  • 受託研究機構
  • 醫院和診所
  • 製藥公司
  • 研究和學術機構

第12章 siRNA治療市場:按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章 siRNA治療市場:依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 siRNA治療市場:依國家分類

  • 美國
  • 德國
  • 中國
  • 英國
  • 印度
  • 日本
  • 俄羅斯
  • 巴西
  • 加拿大
  • 義大利
  • 墨西哥
  • 法國
  • 西班牙
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析,2025年
    • 濃度比(CR)
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析,2025 年
  • 2025年產品系列分析
  • 基準分析,2025 年

第16章:公司簡介

  • Alnylam Pharmaceuticals Inc.
  • Alys Pharmaceuticals Inc.
  • Arbutus Biopharma Corporation
  • Arcturus Therapeutics, Inc. by Alcobra Ltd.
  • Aro Biotherapeutics Co.
  • Arrowhead Pharmaceuticals Inc.
  • Atalanta Therapeutics
  • Biocon Ltd.
  • e-Therapeutics Plc
  • Eli Lilly and Company
  • Ionis Pharmaceuticals Inc.
  • Merck & Co. Inc.
  • Moderna Therapeutics
  • Novartis AG
  • Novo Nordisk A/S
  • Phio Pharmaceuticals, Inc.
  • Quark Pharmaceuticals inc.
  • Risen Pharma Tech Co Ltd
  • Roche Holding AG
  • Shanghai Argo Biopharmaceutical Co., Ltd.
  • Silence Therapeutics plc
  • Sirius Therapeutics Inc.
  • Sirnaomics Inc.
  • Suzhou Sanegene Bio Inc.
  • Synerk Inc.
  • Thermo Fisher Scientific Inc.
  • Vir Biotechnology, Inc.
  • Wave Life Sciences USA, Inc.

第17章 主要專家

Product Code: MRR-FA284DCDE1BC

The siRNA Therapeutics Market is projected to grow by USD 6.61 billion at a CAGR of 10.68% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.25 billion
Estimated Year [2026] USD 3.58 billion
Forecast Year [2032] USD 6.61 billion
CAGR (%) 10.68%

siRNA Therapeutics: Executive Overview

Small interfering RNA (siRNA) therapeutics are medicines designed to selectively silence specific genes by directing cellular machinery to degrade complementary messenger RNA. Their clinical value rests on high target specificity, the ability to address previously difficult protein targets, and the potential for infrequent dosing when delivery systems support durable activity. The field is advancing through improvements in sequence design, chemical stabilization, conjugation, and tissue-directed delivery.

Delivery, Durability, and Translational Progress Are Reshaping the Field

The landscape is shifting from proof of gene silencing toward reliable delivery to clinically relevant tissues. Ligand conjugates, lipid-based systems, and other delivery approaches are being refined to improve uptake, reduce off-target effects, and extend pharmacologic activity. Progress is also being shaped by biomarker-guided development, clearer dose-response characterization, and increasing attention to manufacturing consistency, long-term safety, immune effects, and treatment access.

Artificial Intelligence Accelerates Design, Prioritization, and Development

Artificial intelligence is contributing to siRNA discovery by supporting target identification, sequence optimization, off-target prediction, delivery-material selection, and analysis of transcriptomic and clinical datasets. Its cumulative impact depends on the quality and diversity of training data, experimental validation, and transparent model governance. AI can shorten iteration cycles and improve candidate prioritization, but it does not replace laboratory confirmation, toxicology, regulatory review, or post-treatment monitoring.

Regional Insights: Delivery Capability and Regulatory Readiness Shape Adoption

North America benefits from established biotechnology infrastructure, clinical research capacity, and substantial experience with advanced therapeutics. Europe combines strong academic translational networks with coordinated regulatory and health-technology assessment considerations. Asia-Pacific is supported by expanding biopharmaceutical capabilities and significant research activity, while regional differences in reimbursement and clinical infrastructure remain important. Latin America is developing specialized research and treatment capacity, with access and supply-chain reliability continuing to influence implementation. The Middle East is strengthening precision-medicine and innovation ecosystems, whereas Africa requires sustained investment in clinical networks, diagnostics, cold-chain logistics, and equitable access.

Group Insights: Cooperation and Policy Alignment Influence Scale

ASEAN markets present varied regulatory systems, healthcare capacity, and access conditions, making regional cooperation especially relevant. BRICS members combine large scientific and patient populations with diverse development and reimbursement environments. The European Union offers regulatory coordination alongside country-level differences in health technology assessment and procurement. G7 countries contribute advanced research, manufacturing, and financing capabilities. GCC states are investing in healthcare modernization and precision medicine, while NATO members provide broad research and industrial networks; these groupings are not uniform markets, so implementation strategies must account for national policy and infrastructure differences.

Country Insights: National Strengths Create Different Development Pathways

The United States and Canada combine strong research systems with experienced clinical-development environments. The United Kingdom, Germany, France, Italy, and Spain offer established academic and healthcare networks, while differences in assessment, procurement, and reimbursement affect uptake. China, Japan, South Korea, India, and Australia are strengthening research, manufacturing, and translational capabilities through distinct regulatory and healthcare frameworks. Brazil and Mexico are important Latin American centers for clinical activity and healthcare delivery, with access shaped by institutional capacity and supply chains. Russia maintains scientific and clinical capabilities, although collaboration, procurement, and regulatory conditions require careful assessment.

Strategic Priorities for Leaders in siRNA Therapeutics

Industry leaders should prioritize delivery platforms matched to tissue biology, incorporate off-target and immune-risk testing early, and use clinically meaningful biomarkers to demonstrate durable response. Development plans should integrate manufacturing controls, scalable analytical methods, and clear long-term follow-up. Partnerships with hospitals, diagnostic providers, regulators, and patient organizations can improve trial execution and access planning. AI should be deployed with validated datasets, human oversight, reproducible workflows, and explicit controls for bias, privacy, and model drift. Regional launch strategies should reflect local reimbursement, infrastructure, and treatment-monitoring requirements rather than assuming a uniform global pathway.

Research Methodology: Evidence-Based Assessment of the siRNA Therapeutics Landscape

This executive summary uses a structured synthesis of publicly available scientific literature, clinical-trial records, regulatory documents, health-system information, and authoritative policy and technology sources. Evidence was assessed qualitatively for relevance, recency, methodological strength, and geographic applicability. Findings were organized around therapeutic mechanisms, delivery technologies, development practices, artificial-intelligence applications, and regional, group, and country conditions. No market estimates, market sizing, market shares, or forecasts are presented.

Conclusion: Precision Delivery and Evidence Discipline Will Define Progress

siRNA therapeutics are moving toward a more mature model in which selective gene silencing must be paired with dependable tissue delivery, durable benefit, manageable safety, and practical treatment access. Scientific progress is being reinforced by improved analytics and AI-enabled prioritization, but success remains dependent on experimental validation and robust clinical evidence. Organizations that align platform innovation with manufacturing discipline, regulatory engagement, health-system realities, and patient needs will be best positioned to translate gene-silencing science into durable clinical value.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. siRNA Therapeutics Market, by Drug Agent

  • 7.1. Introduction
  • 7.2. Givosiran
  • 7.3. Inclisiran
  • 7.4. Lumasiran
  • 7.5. Nedosiran
  • 7.6. Patisiran
  • 7.7. Vutrisiran

8. siRNA Therapeutics Market, by Delivery Systems

  • 8.1. Introduction
  • 8.2. Lipid Nanoparticles
  • 8.3. Peptide Delivery Systems
  • 8.4. Polymer Conjugates

9. siRNA Therapeutics Market, by Route of Administration

  • 9.1. Introduction
  • 9.2. Intravenous (IV)
  • 9.3. Subcutaneous

10. siRNA Therapeutics Market, by Therapeutic Categories

  • 10.1. Introduction
  • 10.2. Cardiovascular Disorders
  • 10.3. Immunological Disorders
  • 10.4. Infectious Diseases
    • 10.4.1. Bacterial Infections
    • 10.4.2. Viral Infections
  • 10.5. Metabolic Disorders
  • 10.6. Neurological Disorders
    • 10.6.1. Alzheimer's Disease
    • 10.6.2. Parkinson's Disease
  • 10.7. Oncology
    • 10.7.1. Hematologic Malignancies
      • 10.7.1.1. Leukemia
      • 10.7.1.2. Lymphoma
    • 10.7.2. Solid Tumors
      • 10.7.2.1. Breast Cancer
      • 10.7.2.2. Lung Cancer
      • 10.7.2.3. Prostate Cancer

11. siRNA Therapeutics Market, by End-User

  • 11.1. Introduction
  • 11.2. Contract Research Organizations
  • 11.3. Hospitals & Clinics
  • 11.4. Pharmaceutical Companies
  • 11.5. Research & Academic Institutes

12. siRNA Therapeutics Market, by Region

  • 12.1. Introduction
  • 12.2. Asia-Pacific
  • 12.3. North America
  • 12.4. Latin America
  • 12.5. Europe
  • 12.6. Middle East
  • 12.7. Africa

13. siRNA Therapeutics Market, by Group

  • 13.1. Introduction
  • 13.2. ASEAN
  • 13.3. GCC
  • 13.4. European Union
  • 13.5. BRICS
  • 13.6. G7
  • 13.7. NATO

14. siRNA Therapeutics Market, by Country

  • 14.1. Introduction
  • 14.2. United States
  • 14.3. Germany
  • 14.4. China
  • 14.5. United Kingdom
  • 14.6. India
  • 14.7. Japan
  • 14.8. Russia
  • 14.9. Brazil
  • 14.10. Canada
  • 14.11. Italy
  • 14.12. Mexico
  • 14.13. France
  • 14.14. Spain
  • 14.15. Australia
  • 14.16. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. Market Concentration Analysis, 2025
    • 15.2.1. Concentration Ratio (CR)
    • 15.2.2. Herfindahl Hirschman Index (HHI)
  • 15.3. Recent Developments & Impact Analysis, 2025
  • 15.4. Product Portfolio Analysis, 2025
  • 15.5. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Alnylam Pharmaceuticals Inc.
  • 16.2. Alys Pharmaceuticals Inc.
  • 16.3. Arbutus Biopharma Corporation
  • 16.4. Arcturus Therapeutics, Inc. by Alcobra Ltd.
  • 16.5. Aro Biotherapeutics Co.
  • 16.6. Arrowhead Pharmaceuticals Inc.
  • 16.7. Atalanta Therapeutics
  • 16.8. Biocon Ltd.
  • 16.9. e-Therapeutics Plc
  • 16.10. Eli Lilly and Company
  • 16.11. Ionis Pharmaceuticals Inc.
  • 16.12. Merck & Co. Inc.
  • 16.13. Moderna Therapeutics
  • 16.14. Novartis AG
  • 16.15. Novo Nordisk A/S
  • 16.16. Phio Pharmaceuticals, Inc.
  • 16.17. Quark Pharmaceuticals inc.
  • 16.18. Risen Pharma Tech Co Ltd
  • 16.19. Roche Holding AG
  • 16.20. Shanghai Argo Biopharmaceutical Co., Ltd.
  • 16.21. Silence Therapeutics plc
  • 16.22. Sirius Therapeutics Inc.
  • 16.23. Sirnaomics Inc.
  • 16.24. Suzhou Sanegene Bio Inc.
  • 16.25. Synerk Inc.
  • 16.26. Thermo Fisher Scientific Inc.
  • 16.27. Vir Biotechnology, Inc.
  • 16.28. Wave Life Sciences USA, Inc.

17. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global siRNA Therapeutics Market, Years Considered for the Study
  • FIGURE 2. Global siRNA Therapeutics Market, Research Design
  • FIGURE 3. Global siRNA Therapeutics Market, Research Framework
  • FIGURE 4. Global siRNA Therapeutics Market, Data Triangulation
  • FIGURE 5. Global siRNA Therapeutics Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global siRNA Therapeutics Market Size, by Drug Agent, 2025 vs 2032 (%)
  • FIGURE 7. Global siRNA Therapeutics Market Size, by Drug Agent, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global siRNA Therapeutics Market Size, by Delivery Systems, 2025 vs 2032 (%)
  • FIGURE 9. Global siRNA Therapeutics Market Size, by Delivery Systems, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global siRNA Therapeutics Market Size, by Route of Administration, 2025 vs 2032 (%)
  • FIGURE 11. Global siRNA Therapeutics Market Size, by Route of Administration, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global siRNA Therapeutics Market Size, by Therapeutic Categories, 2025 vs 2032 (%)
  • FIGURE 13. Global siRNA Therapeutics Market Size, by Therapeutic Categories, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global siRNA Therapeutics Market Size, by End-User, 2025 vs 2032 (%)
  • FIGURE 15. Global siRNA Therapeutics Market Size, by End-User, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global siRNA Therapeutics Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 17. Global siRNA Therapeutics Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 18. Global siRNA Therapeutics Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 19. Global siRNA Therapeutics Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 20. Global siRNA Therapeutics Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 21. Global siRNA Therapeutics Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global siRNA Therapeutics Market Segmentation & Coverage
  • TABLE 2. Global siRNA Therapeutics Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global siRNA Therapeutics Market Size, by Drug Agent, 2017-2032 (USD Million)
  • TABLE 4. Global Givosiran Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Givosiran Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Givosiran Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Inclisiran Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Inclisiran Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Inclisiran Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Lumasiran Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global Lumasiran Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global Lumasiran Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global Nedosiran Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 14. Global Nedosiran Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 15. Global Nedosiran Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 16. Global Patisiran Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 17. Global Patisiran Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 18. Global Patisiran Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 19. Global Vutrisiran Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 20. Global Vutrisiran Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 21. Global Vutrisiran Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 22. Global siRNA Therapeutics Market Size, by Delivery Systems, 2017-2032 (USD Million)
  • TABLE 23. Global Lipid Nanoparticles Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 24. Global Lipid Nanoparticles Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 25. Global Lipid Nanoparticles Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 26. Global Peptide Delivery Systems Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 27. Global Peptide Delivery Systems Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 28. Global Peptide Delivery Systems Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 29. Global Polymer Conjugates Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 30. Global Polymer Conjugates Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 31. Global Polymer Conjugates Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 32. Global siRNA Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 33. Global Intravenous (IV) Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 34. Global Intravenous (IV) Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 35. Global Intravenous (IV) Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 36. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 37. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 38. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 39. Global siRNA Therapeutics Market Size, by Therapeutic Categories, 2017-2032 (USD Million)
  • TABLE 40. Global Cardiovascular Disorders Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 41. Global Cardiovascular Disorders Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 42. Global Cardiovascular Disorders Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 43. Global Immunological Disorders Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 44. Global Immunological Disorders Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 45. Global Immunological Disorders Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 46. Global Infectious Diseases Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 47. Global Infectious Diseases Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 48. Global Infectious Diseases Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 49. Global Bacterial Infections Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 50. Global Bacterial Infections Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 51. Global Bacterial Infections Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 52. Global Viral Infections Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 53. Global Viral Infections Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 54. Global Viral Infections Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 55. Global Metabolic Disorders Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 56. Global Metabolic Disorders Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 57. Global Metabolic Disorders Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 58. Global Neurological Disorders Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 59. Global Neurological Disorders Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 60. Global Neurological Disorders Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 61. Global Alzheimer's Disease Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 62. Global Alzheimer's Disease Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 63. Global Alzheimer's Disease Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 64. Global Parkinson's Disease Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 65. Global Parkinson's Disease Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 66. Global Parkinson's Disease Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 67. Global Oncology Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 68. Global Oncology Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 69. Global Oncology Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 70. Global Hematologic Malignancies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 71. Global Hematologic Malignancies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 72. Global Hematologic Malignancies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 73. Global Leukemia Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 74. Global Leukemia Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 75. Global Leukemia Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 76. Global Lymphoma Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 77. Global Lymphoma Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 78. Global Lymphoma Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 79. Global Solid Tumors Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 80. Global Solid Tumors Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 81. Global Solid Tumors Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 82. Global Breast Cancer Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 83. Global Breast Cancer Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 84. Global Breast Cancer Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 85. Global Lung Cancer Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 86. Global Lung Cancer Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 87. Global Lung Cancer Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 88. Global Prostate Cancer Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 89. Global Prostate Cancer Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 90. Global Prostate Cancer Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 91. Global siRNA Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 92. Global Contract Research Organizations Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 93. Global Contract Research Organizations Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 94. Global Contract Research Organizations Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 95. Global Hospitals & Clinics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 96. Global Hospitals & Clinics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 97. Global Hospitals & Clinics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 98. Global Pharmaceutical Companies Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 99. Global Pharmaceutical Companies Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 100. Global Pharmaceutical Companies Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 101. Global Research & Academic Institutes Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 102. Global Research & Academic Institutes Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 103. Global Research & Academic Institutes Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 104. Global siRNA Therapeutics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 105. Asia-Pacific siRNA Therapeutics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 106. Asia-Pacific siRNA Therapeutics Market Size, by Drug Agent, 2017-2032 (USD Million)
  • TABLE 107. Asia-Pacific siRNA Therapeutics Market Size, by Delivery Systems, 2017-2032 (USD Million)
  • TABLE 108. Asia-Pacific siRNA Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 109. Asia-Pacific siRNA Therapeutics Market Size, by Therapeutic Categories, 2017-2032 (USD Million)
  • TABLE 110. Asia-Pacific siRNA Therapeutics Market Size, by Infectious Diseases, 2017-2032 (USD Million)
  • TABLE 111. Asia-Pacific siRNA Therapeutics Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 112. Asia-Pacific siRNA Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 113. Asia-Pacific siRNA Therapeutics Market Size, by Hematologic Malignancies, 2017-2032 (USD Million)
  • TABLE 114. Asia-Pacific siRNA Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
  • TABLE 115. Asia-Pacific siRNA Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 116. North America siRNA Therapeutics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 117. North America siRNA Therapeutics Market Size, by Drug Agent, 2017-2032 (USD Million)
  • TABLE 118. North America siRNA Therapeutics Market Size, by Delivery Systems, 2017-2032 (USD Million)
  • TABLE 119. North America siRNA Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 120. North America siRNA Therapeutics Market Size, by Therapeutic Categories, 2017-2032 (USD Million)
  • TABLE 121. North America siRNA Therapeutics Market Size, by Infectious Diseases, 2017-2032 (USD Million)
  • TABLE 122. North America siRNA Therapeutics Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 123. North America siRNA Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 124. North America siRNA Therapeutics Market Size, by Hematologic Malignancies, 2017-2032 (USD Million)
  • TABLE 125. North America siRNA Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
  • TABLE 126. North America siRNA Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 127. Latin America siRNA Therapeutics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 128. Latin America siRNA Therapeutics Market Size, by Drug Agent, 2017-2032 (USD Million)
  • TABLE 129. Latin America siRNA Therapeutics Market Size, by Delivery Systems, 2017-2032 (USD Million)
  • TABLE 130. Latin America siRNA Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 131. Latin America siRNA Therapeutics Market Size, by Therapeutic Categories, 2017-2032 (USD Million)
  • TABLE 132. Latin America siRNA Therapeutics Market Size, by Infectious Diseases, 2017-2032 (USD Million)
  • TABLE 133. Latin America siRNA Therapeutics Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 134. Latin America siRNA Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 135. Latin America siRNA Therapeutics Market Size, by Hematologic Malignancies, 2017-2032 (USD Million)
  • TABLE 136. Latin America siRNA Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
  • TABLE 137. Latin America siRNA Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 138. Europe siRNA Therapeutics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 139. Europe siRNA Therapeutics Market Size, by Drug Agent, 2017-2032 (USD Million)
  • TABLE 140. Europe siRNA Therapeutics Market Size, by Delivery Systems, 2017-2032 (USD Million)
  • TABLE 141. Europe siRNA Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 142. Europe siRNA Therapeutics Market Size, by Therapeutic Categories, 2017-2032 (USD Million)
  • TABLE 143. Europe siRNA Therapeutics Market Size, by Infectious Diseases, 2017-2032 (USD Million)
  • TABLE 144. Europe siRNA Therapeutics Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 145. Europe siRNA Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 146. Europe siRNA Therapeutics Market Size, by Hematologic Malignancies, 2017-2032 (USD Million)
  • TABLE 147. Europe siRNA Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
  • TABLE 148. Europe siRNA Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 149. Middle East siRNA Therapeutics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 150. Middle East siRNA Therapeutics Market Size, by Drug Agent, 2017-2032 (USD Million)
  • TABLE 151. Middle East siRNA Therapeutics Market Size, by Delivery Systems, 2017-2032 (USD Million)
  • TABLE 152. Middle East siRNA Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 153. Middle East siRNA Therapeutics Market Size, by Therapeutic Categories, 2017-2032 (USD Million)
  • TABLE 154. Middle East siRNA Therapeutics Market Size, by Infectious Diseases, 2017-2032 (USD Million)
  • TABLE 155. Middle East siRNA Therapeutics Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 156. Middle East siRNA Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 157. Middle East siRNA Therapeutics Market Size, by Hematologic Malignancies, 2017-2032 (USD Million)
  • TABLE 158. Middle East siRNA Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
  • TABLE 159. Middle East siRNA Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 160. Africa siRNA Therapeutics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 161. Africa siRNA Therapeutics Market Size, by Drug Agent, 2017-2032 (USD Million)
  • TABLE 162. Africa siRNA Therapeutics Market Size, by Delivery Systems, 2017-2032 (USD Million)
  • TABLE 163. Africa siRNA Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 164. Africa siRNA Therapeutics Market Size, by Therapeutic Categories, 2017-2032 (USD Million)
  • TABLE 165. Africa siRNA Therapeutics Market Size, by Infectious Diseases, 2017-2032 (USD Million)
  • TABLE 166. Africa siRNA Therapeutics Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 167. Africa siRNA Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 168. Africa siRNA Therapeutics Market Size, by Hematologic Malignancies, 2017-2032 (USD Million)
  • TABLE 169. Africa siRNA Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
  • TABLE 170. Africa siRNA Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 171. Global siRNA Therapeutics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 172. ASEAN siRNA Therapeutics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 173. ASEAN siRNA Therapeutics Market Size, by Drug Agent, 2017-2032 (USD Million)
  • TABLE 174. ASEAN siRNA Therapeutics Market Size, by Delivery Systems, 2017-2032 (USD Million)
  • TABLE 175. ASEAN siRNA Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 176. ASEAN siRNA Therapeutics Market Size, by Therapeutic Categories, 2017-2032 (USD Million)
  • TABLE 177. ASEAN siRNA Therapeutics Market Size, by Infectious Diseases, 2017-2032 (USD Million)
  • TABLE 178. ASEAN siRNA Therapeutics Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 179. ASEAN siRNA Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 180. ASEAN siRNA Therapeutics Market Size, by Hematologic Malignancies, 2017-2032 (USD Million)
  • TABLE 181. ASEAN siRNA Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
  • TABLE 182. ASEAN siRNA Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 183. GCC siRNA Therapeutics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 184. GCC siRNA Therapeutics Market Size, by Drug Agent, 2017-2032 (USD Million)
  • TABLE 185. GCC siRNA Therapeutics Market Size, by Delivery Systems, 2017-2032 (USD Million)
  • TABLE 186. GCC siRNA Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 187. GCC siRNA Therapeutics Market Size, by Therapeutic Categories, 2017-2032 (USD Million)
  • TABLE 188. GCC siRNA Therapeutics Market Size, by Infectious Diseases, 2017-2032 (USD Million)
  • TABLE 189. GCC siRNA Therapeutics Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 190. GCC siRNA Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 191. GCC siRNA Therapeutics Market Size, by Hematologic Malignancies, 2017-2032 (USD Million)
  • TABLE 192. GCC siRNA Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
  • TABLE 193. GCC siRNA Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 194. European Union siRNA Therapeutics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 195. European Union siRNA Therapeutics Market Size, by Drug Agent, 2017-2032 (USD Million)
  • TABLE 196. European Union siRNA Therapeutics Market Size, by Delivery Systems, 2017-2032 (USD Million)
  • TABLE 197. European Union siRNA Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 198. European Union siRNA Therapeutics Market Size, by Therapeutic Categories, 2017-2032 (USD Million)
  • TABLE 199. European Union siRNA Therapeutics Market Size, by Infectious Diseases, 2017-2032 (USD Million)
  • TABLE 200. European Union siRNA Therapeutics Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 201. European Union siRNA Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 202. European Union siRNA Therapeutics Market Size, by Hematologic Malignancies, 2017-2032 (USD Million)
  • TABLE 203. European Union siRNA Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
  • TABLE 204. European Union siRNA Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 205. BRICS siRNA Therapeutics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 206. BRICS siRNA Therapeutics Market Size, by Drug Agent, 2017-2032 (USD Million)
  • TABLE 207. BRICS siRNA Therapeutics Market Size, by Delivery Systems, 2017-2032 (USD Million)
  • TABLE 208. BRICS siRNA Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 209. BRICS siRNA Therapeutics Market Size, by Therapeutic Categories, 2017-2032 (USD Million)
  • TABLE 210. BRICS siRNA Therapeutics Market Size, by Infectious Diseases, 2017-2032 (USD Million)
  • TABLE 211. BRICS siRNA Therapeutics Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 212. BRICS siRNA Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 213. BRICS siRNA Therapeutics Market Size, by Hematologic Malignancies, 2017-2032 (USD Million)
  • TABLE 214. BRICS siRNA Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
  • TABLE 215. BRICS siRNA Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 216. G7 siRNA Therapeutics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 217. G7 siRNA Therapeutics Market Size, by Drug Agent, 2017-2032 (USD Million)
  • TABLE 218. G7 siRNA Therapeutics Market Size, by Delivery Systems, 2017-2032 (USD Million)
  • TABLE 219. G7 siRNA Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 220. G7 siRNA Therapeutics Market Size, by Therapeutic Categories, 2017-2032 (USD Million)
  • TABLE 221. G7 siRNA Therapeutics Market Size, by Infectious Diseases, 2017-2032 (USD Million)
  • TABLE 222. G7 siRNA Therapeutics Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 223. G7 siRNA Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 224. G7 siRNA Therapeutics Market Size, by Hematologic Malignancies, 2017-2032 (USD Million)
  • TABLE 225. G7 siRNA Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
  • TABLE 226. G7 siRNA Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 227. NATO siRNA Therapeutics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 228. NATO siRNA Therapeutics Market Size, by Drug Agent, 2017-2032 (USD Million)
  • TABLE 229. NATO siRNA Therapeutics Market Size, by Delivery Systems, 2017-2032 (USD Million)
  • TABLE 230. NATO siRNA Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 231. NATO siRNA Therapeutics Market Size, by Therapeutic Categories, 2017-2032 (USD Million)
  • TABLE 232. NATO siRNA Therapeutics Market Size, by Infectious Diseases, 2017-2032 (USD Million)
  • TABLE 233. NATO siRNA Therapeutics Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 234. NATO siRNA Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 235. NATO siRNA Therapeutics Market Size, by Hematologic Malignancies, 2017-2032 (USD Million)
  • TABLE 236. NATO siRNA Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
  • TABLE 237. NATO siRNA Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 238. Global siRNA Therapeutics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 239. United States siRNA Therapeutics Market Size, 2017-2032 (USD Million)
  • TABLE 240. United States siRNA Therapeutics Market Size, by Drug Agent, 2017-2032 (USD Million)
  • TABLE 241. United States siRNA Therapeutics Market Size, by Delivery Systems, 2017-2032 (USD Million)
  • TABLE 242. United States siRNA Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 243. United States siRNA Therapeutics Market Size, by Therapeutic Categories, 2017-2032 (USD Million)
  • TABLE 244. United States siRNA Therapeutics Market Size, by Infectious Diseases, 2017-2032 (USD Million)
  • TABLE 245. United States siRNA Therapeutics Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 246. United States siRNA Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 247. United States siRNA Therapeutics Market Size, by Hematologic Malignancies, 2017-2032 (USD Million)
  • TABLE 248. United States siRNA Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
  • TABLE 249. United States siRNA Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 250. Germany siRNA Therapeutics Market Size, 2017-2032 (USD Million)
  • TABLE 251. Germany siRNA Therapeutics Market Size, by Drug Agent, 2017-2032 (USD Million)
  • TABLE 252. Germany siRNA Therapeutics Market Size, by Delivery Systems, 2017-2032 (USD Million)
  • TABLE 253. Germany siRNA Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 254. Germany siRNA Therapeutics Market Size, by Therapeutic Categories, 2017-2032 (USD Million)
  • TABLE 255. Germany siRNA Therapeutics Market Size, by Infectious Diseases, 2017-2032 (USD Million)
  • TABLE 256. Germany siRNA Therapeutics Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 257. Germany siRNA Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 258. Germany siRNA Therapeutics Market Size, by Hematologic Malignancies, 2017-2032 (USD Million)
  • TABLE 259. Germany siRNA Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
  • TABLE 260. Germany siRNA Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 261. China siRNA Therapeutics Market Size, 2017-2032 (USD Million)
  • TABLE 262. China siRNA Therapeutics Market Size, by Drug Agent, 2017-2032 (USD Million)
  • TABLE 263. China siRNA Therapeutics Market Size, by Delivery Systems, 2017-2032 (USD Million)
  • TABLE 264. China siRNA Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 265. China siRNA Therapeutics Market Size, by Therapeutic Categories, 2017-2032 (USD Million)
  • TABLE 266. China siRNA Therapeutics Market Size, by Infectious Diseases, 2017-2032 (USD Million)
  • TABLE 267. China siRNA Therapeutics Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 268. China siRNA Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 269. China siRNA Therapeutics Market Size, by Hematologic Malignancies, 2017-2032 (USD Million)
  • TABLE 270. China siRNA Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
  • TABLE 271. China siRNA Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 272. United Kingdom siRNA Therapeutics Market Size, 2017-2032 (USD Million)
  • TABLE 273. United Kingdom siRNA Therapeutics Market Size, by Drug Agent, 2017-2032 (USD Million)
  • TABLE 274. United Kingdom siRNA Therapeutics Market Size, by Delivery Systems, 2017-2032 (USD Million)
  • TABLE 275. United Kingdom siRNA Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 276. United Kingdom siRNA Therapeutics Market Size, by Therapeutic Categories, 2017-2032 (USD Million)
  • TABLE 277. United Kingdom siRNA Therapeutics Market Size, by Infectious Diseases, 2017-2032 (USD Million)
  • TABLE 278. United Kingdom siRNA Therapeutics Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 279. United Kingdom siRNA Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 280. United Kingdom siRNA Therapeutics Market Size, by Hematologic Malignancies, 2017-2032 (USD Million)
  • TABLE 281. United Kingdom siRNA Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
  • TABLE 282. United Kingdom siRNA Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 283. India siRNA Therapeutics Market Size, 2017-2032 (USD Million)
  • TABLE 284. India siRNA Therapeutics Market Size, by Drug Agent, 2017-2032 (USD Million)
  • TABLE 285. India siRNA Therapeutics Market Size, by Delivery Systems, 2017-2032 (USD Million)
  • TABLE 286. India siRNA Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 287. India siRNA Therapeutics Market Size, by Therapeutic Categories, 2017-2032 (USD Million)
  • TABLE 288. India siRNA Therapeutics Market Size, by Infectious Diseases, 2017-2032 (USD Million)
  • TABLE 289. India siRNA Therapeutics Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 290. India siRNA Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 291. India siRNA Therapeutics Market Size, by Hematologic Malignancies, 2017-2032 (USD Million)
  • TABLE 292. India siRNA Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
  • TABLE 293. India siRNA Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 294. Japan siRNA Therapeutics Market Size, 2017-2032 (USD Million)
  • TABLE 295. Japan siRNA Therapeutics Market Size, by Drug Agent, 2017-2032 (USD Million)
  • TABLE 296. Japan siRNA Therapeutics Market Size, by Delivery Systems, 2017-2032 (USD Million)
  • TABLE 297. Japan siRNA Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 298. Japan siRNA Therapeutics Market Size, by Therapeutic Categories, 2017-2032 (USD Million)
  • TABLE 299. Japan siRNA Therapeutics Market Size, by Infectious Diseases, 2017-2032 (USD Million)
  • TABLE 300. Japan siRNA Therapeutics Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 301. Japan siRNA Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 302. Japan siRNA Therapeutics Market Size, by Hematologic Malignancies, 2017-2032 (USD Million)
  • TABLE 303. Japan siRNA Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
  • TABLE 304. Japan siRNA Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 305. Russia siRNA Therapeutics Market Size, 2017-2032 (USD Million)
  • TABLE 306. Russia siRNA Therapeutics Market Size, by Drug Agent, 2017-2032 (USD Million)
  • TABLE 307. Russia siRNA Therapeutics Market Size, by Delivery Systems, 2017-2032 (USD Million)
  • TABLE 308. Russia siRNA Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 309. Russia siRNA Therapeutics Market Size, by Therapeutic Categories, 2017-2032 (USD Million)
  • TABLE 310. Russia siRNA Therapeutics Market Size, by Infectious Diseases, 2017-2032 (USD Million)
  • TABLE 311. Russia siRNA Therapeutics Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 312. Russia siRNA Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 313. Russia siRNA Therapeutics Market Size, by Hematologic Malignancies, 2017-2032 (USD Million)
  • TABLE 314. Russia siRNA Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
  • TABLE 315. Russia siRNA Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 316. Brazil siRNA Therapeutics Market Size, 2017-2032 (USD Million)
  • TABLE 317. Brazil siRNA Therapeutics Market Size, by Drug Agent, 2017-2032 (USD Million)
  • TABLE 318. Brazil siRNA Therapeutics Market Size, by Delivery Systems, 2017-2032 (USD Million)
  • TABLE 319. Brazil siRNA Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 320. Brazil siRNA Therapeutics Market Size, by Therapeutic Categories, 2017-2032 (USD Million)
  • TABLE 321. Brazil siRNA Therapeutics Market Size, by Infectious Diseases, 2017-2032 (USD Million)
  • TABLE 322. Brazil siRNA Therapeutics Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 323. Brazil siRNA Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 324. Brazil siRNA Therapeutics Market Size, by Hematologic Malignancies, 2017-2032 (USD Million)
  • TABLE 325. Brazil siRNA Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
  • TABLE 326. Brazil siRNA Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 327. Canada siRNA Therapeutics Market Size, 2017-2032 (USD Million)
  • TABLE 328. Canada siRNA Therapeutics Market Size, by Drug Agent, 2017-2032 (USD Million)
  • TABLE 329. Canada siRNA Therapeutics Market Size, by Delivery Systems, 2017-2032 (USD Million)
  • TABLE 330. Canada siRNA Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 331. Canada siRNA Therapeutics Market Size, by Therapeutic Categories, 2017-2032 (USD Million)
  • TABLE 332. Canada siRNA Therapeutics Market Size, by Infectious Diseases, 2017-2032 (USD Million)
  • TABLE 333. Canada siRNA Therapeutics Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 334. Canada siRNA Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 335. Canada siRNA Therapeutics Market Size, by Hematologic Malignancies, 2017-2032 (USD Million)
  • TABLE 336. Canada siRNA Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
  • TABLE 337. Canada siRNA Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 338. Italy siRNA Therapeutics Market Size, 2017-2032 (USD Million)
  • TABLE 339. Italy siRNA Therapeutics Market Size, by Drug Agent, 2017-2032 (USD Million)
  • TABLE 340. Italy siRNA Therapeutics Market Size, by Delivery Systems, 2017-2032 (USD Million)
  • TABLE 341. Italy siRNA Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 342. Italy siRNA Therapeutics Market Size, by Therapeutic Categories, 2017-2032 (USD Million)
  • TABLE 343. Italy siRNA Therapeutics Market Size, by Infectious Diseases, 2017-2032 (USD Million)
  • TABLE 344. Italy siRNA Therapeutics Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 345. Italy siRNA Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 346. Italy siRNA Therapeutics Market Size, by Hematologic Malignancies, 2017-2032 (USD Million)
  • TABLE 347. Italy siRNA Therapeutics Market Size, by Solid Tumors, 2017-2032 (USD Million)
  • TABLE 348. Italy siRNA Therapeutics Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 349. Mexico siRNA Therapeutics Market Size, 2017-2032 (USD Million)
  • TABLE 350. Mexico siRNA Therapeutics Market Size, by Drug Agent, 2017-2032 (USD Million)
  • TABLE 351. Mexico siRNA Therapeutics Market Size, by Delivery Systems, 2017-2032 (USD Million)
  • TABLE 352. Mexico siRNA Therapeutics Market Size, by Route of Administration, 2017-2032 (USD Million)
  • TABLE 353. Mexico siRNA Therapeutics Market Size, by Therapeutic Categories, 2017-2032 (USD Million)
  • TABLE 354. Mexico siRNA Therapeutics Market Size, by Infectious Diseases, 2017-2032 (USD Million)
  • TABLE 355. Mexico siRNA Therapeutics Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 356. Mexico siRNA Therapeutics Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 357. Mexico siRNA Therapeutics Market Size, by Hematologic Malignancies, 2017-2032 (USD Million)
  • TABLE 358. Mexico